iBio (IBIO)
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and o...
- Open
- 1.450
- High
- 1.468
- Low
- 1.400
- Prev. Close
- 1.450
- Volume
- 580.26K
- Turnover
- 833.64K
- Avg Price
- 1.437
- Bid/Ask Ratio
- 0.00%
- Amplitude
- 4.69%
- 52wk High
- 3.820
- Volume Ratio
- 2.04
- Turnover Ratio
- 2.32%
iBio Analyst Rating
View moreForecast & Rating
Aug 11, 2026Price forecast
$5.40273.70%
Forecast & RatingStrong buy
8analysts
- Strong buy87.50%
- Buy12.50%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · Aug 9 at 03:14 AM
iBio, Inc. (NASDAQ:IBIO) Given Average Rating of "Buy" by Analysts
- rttnews · Aug 4 at 07:06 AM
IBio Names Molly Carr As Chief Medical Officer
- PUBT · Aug 4 at 06:17 AM
iBio files Form 3 for Chief Medical Officer Molly Carr
- PUBT · Aug 4 at 06:06 AM
iBio names endocrinologist Molly Carr as chief medical officer
- Tip Ranks · Jul 17 at 04:31 PM
iBio Updates Governance Deadlines for 2026 Annual Meeting
- Tip Ranks · Jul 1 at 02:15 PM
Buy Rating Reiterated on iBio as IBIO-610 Data Underscore Differentiated Efficacy; $5 Price Target Maintained
